Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV
Status:
Terminated
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety and efficacy of 30mg daily dose of clevudine
(L-FMAU) at 24 weeks of treatment in chronic HBV infected patients with HBeAg negative